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Association of interleukin-10 gene G-1082A polymorphism
with the progression of primary glomerulonephritis.
Background. Interleukin-10 (IL-10) is a cytokine with im-
munosuppressive properties. We evaluated the influence of
G-1082A polymorphism in the IL-10 gene promoter, which
has been associated with modified IL-10 production, on the
two most common forms of primary glomerulonephritis: IgA
nephropathy (IgAN) and focal segmental glomerulosclerosis
(FSGS).
Methods. We studied Caucasian patients (N = 191) with
biopsy-proven glomerulonephritis (IgAN: N = 123, FSGS: N =
68) followed-up for 6.5 ± 5.5 years. Patients were classified ac-
cording to the slope of reciprocal serum creatinine (≥ or <−0.1
dL∗ mg−1 ∗ year−1) into group A (slow progressors, IgAN: N =
75, FSGS: N = 47) and group B (fast progressors, IgAN: N = 48,
FSGS: N = 21). One hundred healthy volunteers were analyzed
as control patients. G-1082A polymorphism was determined by
polymerase chain reaction (PCR) amplification.
Results. The allele frequencies were similar in patients and
control group (NS). Initial renal function, proteinuria, and
blood pressure did not differ significantly between patients
with different genotypes. G-1082A polymorphism was associ-
ated with the progression of both IgAN and FSGS: GA/AA
genotypes were more frequent in group B (fast progressors)
than in group A (slow progressors; P = 0.012 for IgAN, P <
0.05 for FSGS). Patients with the GA/AA genotypes showed a
worse outcome in the Kaplan-Meier analysis of renal survival
(P < 0.05 for both IgAN and FSGS). The IL-10 polymorphism
remained an independent risk factor for progression in multi-
variate analysis (Cox regression model, P < 0.05 for IgAN and
FSGS).
Conclusion. Our results suggest that IL-10 gene G-1082A
polymorphism is an important marker of progression in patients
with IgAN and FSGS.
Primary glomerulonephritis remains one of the ma-
jor causes of end-stage renal disease (ESRD). The two
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most common forms of primary glomerulonephritis are
IgA nephropathy (IgAN) and focal segmental glomeru-
losclerosis (FSGS) [1, 2]. IgAN is characterized by mesan-
gial deposition of immunoglobin A, matrix expansion,
and cellular proliferation. The clinical course of IgA
nephropathy is variable, ranging from stable renal func-
tion over decades to terminal renal failure within few
years. About 10% to 20% of the patients progress to end-
stage renal disease (ESRD) in the first decade after re-
nal biopsy [1]. Clinical predictors including impairment
of renal function, severe proteinuria, and arterial hyper-
tension at presentation have been associated with an
unfavorable outcome [3]. Primary focal segmental
glomerulosclerosis refers to a specific renal histologic le-
sion [i.e., sclerosis found in a portion (segment) of some
(focal) glomeruli without identifiable underlying cause].
It appears to be a disease with different entities, which
are difficult to distinguish in morphologic terms. Whereas
two thirds progress to ESRD within five to 10 years, oth-
ers have a more benign course with complete remission
in a short time, or slow progression over many years.
Efforts to identify these two groups have led to the identi-
fication of risk factors such as increased plasma creatinine
on diagnosis, high proteinuria, and therapy-refractory
nephrotic syndrome, but clear-cut criteria for an individ-
ual prognosis and targeted therapy have not yet been
established [2]. The pathogenetic mechanisms of both
IgAN and FSGS are still under research. Several factors
point to the possible role of genetic influences on their
development and outcome. Familiar forms of both IgAN
[4] and FSGS [5] have been described. A linkage of IgAN
to chromosome 6q22-q23 has been demonstrated [6],
and the genetic disorder underlying the “Finnish type”
of hereditary FSGS [7] and autosomal-recessive steroid-
resistant nephrotic syndrome [8] has been identified. Fur-
thermore, there is a growing body of evidence supporting
a pivotal role of cytokines and chemokines in glomerular
inflammation in primary glomerulonephritis [9].
Interleukin 10 (IL-10) is a pleiotropic cytokine pro-
duced by T-helper type 2 (Th2) cells, B cells, monocytes,
and macrophages. It inhibits a broad array of immune
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parameters including Th1 lymphocyte cytokine produc-
tion, antigen presentation, and antigen-specific T-cell
proliferation, and could play a role as a natural blocking
agent in the inflammation mediated by proinflammatory
cytokines [10]. The mechanisms regulating IL-10 produc-
tion are still under study. It appears that different cells
respond differently to each stimulus, and their response
depends on the cell type and the microenvironment of
the cell. Like many other cytokines, the amount of IL-10
produced on a specific stimulus is subject to genetic reg-
ulation. Turner et al demonstrated a difference in IL-10
secretion in vitro in association with the presence or ab-
sence of the A-allele at position −1082 of the human
IL-10 promoter after concanavalin A stimulation of pe-
ripheral blood mononuclear cells [11]. Reduced IL-10
serum levels were also observed in vivo in the “low IL-
10 producer” GA/AA genotypes (presence of −1082A
allele) [12].
Because of its regulatory functions in both cellular and
humoral immune responses, IL-10 is a candidate media-
tor in controlling renal inflammation. In the present study,
we evaluated the role of IL-10 gene G-1082A polymor-
phism in the clinical course of IgAN and FSGS. Our aim
was to identify genetically determined subgroups of pa-
tients with primary glomerulonephritis who had a more
rapid decline in renal function and earlier onset of ESRD.
The identification of genetic factors that may explain the
clinical variability of IgAN and FSGS is critical for under-
standing their pathogenesis and formulating future ther-
apeutic strategies.
METHODS
Patients and control patients
We studied Caucasian patients (N = 191; 128 males
and 63 females) with biopsy-proven primary glomeru-
lonephritis (IgA: N = 123, FSGS: N = 68) treated in our
center from 1968 to 2003. The mean follow-up period was
6.5 ± 5.5 years, and included monitoring of serum crea-
tinine, endogenous creatinine clearance (24-hour urine
collection), proteinuria, blood pressure, and antihyper-
tensive medication. Arterial hypertension was defined by
the presence of blood pressure values over 140 mm Hg
systolic and/or 90 mm Hg diastolic or the need for anti-
hypertensive treatment. A mean of 19.5 ± 16 data points
were retrieved. Only patients followed-up for at least one
year were included. The slope of reciprocal serum creati-
nine (1/Cr) against time was used to evaluate the progres-
sion of the disease. Patients were classified accordingly
into group A (≥−0.1 dL · mg−1 · year−1, slow progressors,
IgAN: N = 75, FSGS: N = 47) and group B (<−0.1 dL ·
mg−1 · year−1, fast progressors, IgAN: N = 48, FSGS: N =
21). One hundred age-matched volunteers (44 males and
56 females), mainly health staff, without history of kid-
ney diseases or arterial hypertension, served as a control
group. Their mean age was 40 ± 16 years. Whole blood
samples were taken from all patients and control patients
for DNA analysis. The present study was approved by the
local ethics committee.
Determination of IL-10 gene G-1082A polymorphism
Genomic DNA was extracted from peripheral leuko-
cytes from whole blood samples using the QIAmp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Two different poly-
merase chain reaction (PCR) amplifications, each one
specific for each allele, were carried out using the fol-
lowing primers: generic primer (antisense): 5′ CAGTGC
CAACTGAGAATTTGG 3′; sense primer: G-allele spe-
cific PCR: 5′ CTACTAA GGCTTCTTGGGAG 3′, A-
allele specific PCR 5′ ACTACTAAGGCTTCTTGGG
AA 3′ (MWG Biotech AG, Ebersberg, Germany). Ther-
mocycling included an initial denaturation step (5 min-
utes at 95◦C) and 30 cycles consisting of 30 seconds at
95◦C, 40 seconds at 65◦C, and 70 seconds at 72◦C, fol-
lowed by a final extension step at 72◦C for 7 minutes. A
661-bp long sequence of the b-actin gene was amplified as
an internal control in each sample. The combined agarose
gel electrophoresis of the PCR products (both 258-bp
long) allowed determination of the G-1082A genotype.
Internal and external controls were used in order to pro-
hibit misclassifications during genotyping. All PCR pro-
tocols were evaluated by two independent investigators
who were blinded for the phenotype of the samples.
Statistical analysis
Data were expressed as percentages or mean ± stan-
dard deviation. Pearson’s chi-square was used for cate-
gorical data. Continuous variables were tested in each
group for normal distribution using the Kolmogorov-
Smirnov test for one variable. Differences between two
groups were tested with the Student t test or the nonpara-
metric Mann-Whitney U test. The expected allele fre-
quencies under the assumption of the Hardy-Weinberg
equilibrium were compared with the observed frequen-
cies in each study population. Both genotype and allele
frequencies were compared in the different groups in
order to reduce the possibility of spurious associations.
The individual rate of progression of renal insufficiency
was calculated as the slope of reciprocal serum creati-
nine versus time plot (linear regression). The Kaplan-
Meier method using a log-rank test was employed for
survival analysis of the kidney as a functioning organ.
The end points included ERSD or doubling of the ini-
tial serum creatinine [13]. A Cox regression model was
used for multivariate analysis. The following covariates
were tested: sex, age, serum creatinine, proteinuria, and
blood pressure at the time of renal biopsy, and IL-10 gene
polymorphism. Statistical analysis was performed using
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Table 1. Clinical and laboratory parameters at the time of renal biopsy (mean ± SD) in N = 123 patients with IgAN and N = 68 patients with
FSGS according to the IL-10 G-1082A genotype
IgAN FSGS
GG genotype GA/AA genotype Significance GG genotype GA/AA genotype Significance
Number N 24 99 22 46
Age years 33.7 ± 15 38.2 ± 13 NS 49.0 ± 17 37.5 ± 17 P < 0.05a
Creatinine mg/dL 1.9 ± 1.0 2.1 ± 1.5 NS 1.4 ± 0.6 1.6 ± 1.0 NS
Ccr mL/min/1.73m2 72.5 ± 31 72.1 ± 38 NS 84.1 ± 33 93.9 ± 36 NS
Proteinuria g/24h 3.8 ± 3.2 4.1 ± 2.8 NS 13.5 ± 12.6 9.8 ± 8.6 NS
Arterial hypertension % 79.1 81.8 NS 72.7 73.3 NS
MAP mm Hg 112.4 ± 14 112.1 ± 12 NS 107.2 ± 12 109.6 ± 10 NS
Antihypertensives N 2.2 ± 1.4 2.2 ± 1.2 NS 1.8 ± 1.1 2.0 ± 1.2 NS
ACE inhibition % 50.0 66.3 NS 45.5 69.8 P = 0.057b
Corticosteroids % 12.5 15.2 NS 22.7 17.4 NS
Corticosteroids + CSA % – – – 54.5 58.7 NS
Abbreviations are: Ccr, creatinine clearance; MAP, mean arterial blood pressure; ACE, angiotensin-converting enzyme; CSA, cyclosporine.
aStudent t test.
bChi-square test.
the SPSS 10.0 program (Statistical Package for Social
Sciences, SSPS GmbH, Munich, Germany). All tests were
two-sided and statistical significance was defined as P <
0.05.
RESULTS
Patient characteristics
IgA nephropathy. Our IgAN cohort consisted of Cau-
casian patients (93 males and 30 females; N = 123). Their
mean age at diagnosis was 37.1 ± 14 years. The mean
serum creatinine was 2.1 ± 1.4 mg/dL, the creatinine
clearance 72.2 ± 36 mL/min/1.73m2, and the mean pro-
teinuria 4.0 ± 2.9 g/24h. Seventy-five patients belonged to
group A (slow progressors) and N = 48 to group B (fast
progressors). Seventy-five patients (61%) were treated
with ACE inhibitors. The percentage of treated patients
tended to be higher in group A (slow progressors, 69%)
than in group B (fast progressors, 54%, P = 0.10). Four
patients receiving angiotensin II type 1 receptor antago-
nists were excluded from this analysis. There were no rele-
vant differences regarding the number of patients treated
with corticosteroids in group A (13.3%) and in group B
(16.7%, NS). At the time of genotyping, N = 80 patients
(65%) had reached ERSD, and N = 7 (6%) had reached
only the second end point (doubling of the initial serum
creatinine). As far as nongenetic factors were concerned,
renal function at renal biopsy (Cox regression: P < 0.001),
the amount of proteinuria (P < 0.001), and blood pres-
sure values (P < 0.01), but not gender or age (NS) were
associated with the progression of IgAN. Patients who
underwent renal biopsy in the last 15 years tended to ac-
celerated progression, probably because of the fact that
increasing numbers of patients with unfavorable clinical
course were referred to our department by nephrologists,
as it developed to a glomerulonephritis referral center in
the last decades.
Focal segmental glomerulosclerosis. This examination
involved 68 Caucasian patients, 33 women and 35 men,
with biopsy-confirmed primary FSGS. Their mean age at
diagnosis was 41.2 ± 18 years. The mean serum creati-
nine was 1.5 ± 0.9 mg/dL, the creatinine clearance 90.2 ±
35 mL/min/1.73m2, and the mean proteinuria 11.2 ±
10.2 g/24h. Forty-seven patients with FSGS belonged to
group A (slow progressors), and N = 21 to group B
(fast progressors). Regarding treatment, 62.2% of the
patients in group A received ACE inhibitors compared
with 60.0% in group B (NS). Furthermore, there were no
relevant differences concerning the number of patients
treated with immunosuppressive drugs (corticosteroids:
group A: 21.3%, group B: 14.3%; corticosteroids and cy-
closporine: group A: 53.2%, group B: 66.7%, NS). At the
time of genotyping, N = 27 patients (40%) had reached
ERSD, and N = 10 (15%) had reached only the sec-
ond end point (doubling of the initial serum creatinine).
Increased serum creatinine (Cox regression: P < 0.001)
and higher blood pressure values (P < 0.01) were asso-
ciated with a worse prognosis in our patients with FSGS.
As in the case of IgAN, patients with FSGS diagnosed in
the last 15 years tended to have more rapidly declining
renal function.
IL-10 genotyping and parameters at the time
of renal biopsy
The allele frequencies of G-1082A polymorphism were
similar in control subjects (G-allele: 0.43, A-allele: 0.57)
and patients with IgAN (G-allele: 0.41, A-allele: 0.59,
NS) or FSGS (G-allele: 0.52, A-allele: 0.48, NS). In all
groups the observed genotype frequencies corresponded
to the expected values according to the Hardy-Weinberg
equilibrium. There were no relevant differences at the
time of renal biopsy in terms of renal function, protein-
uria, and blood pressure between patients with different
G-1082A genotypes in both IgAN and FSGS (Table 1,
NS). Patients with FSGS and the GA/AA genotypes
underwent renal biopsy at a younger age (P < 0.05,
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Fig. 1. Genotype distribution of IL-10 gene G-1082A polymorphism
in group A (slow progressors) and group B (fast progressors) in patients
with biopsy-proven IgA nephropathy (N = 123). †Chi-square test.
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Fig. 2. Kaplan-Meier analysis of the kidney survival in patients with
biopsy-proven IgA nephropathy (N = 123) in relationship with the IL-
10 gene G-1082A polymorphism. Number of patients at risk, 5 years
after renal biopsy: GG, N = 9; GA/AA, N = 32; 10 years after renal
biopsy: GG, N = 3; GA/AA, N = 9. †Log-rank test.
Table 1). No significant difference in the number of pa-
tients with different G-1082A genotypes treated with
ACE inhibitors or immunosuppressive agents was ob-
served in either glomerulonephritis forms (Table 1, NS).
IL-10 genotype and progression
IgA nephropathy. G-1082A polymorphism was asso-
ciated with the progression of IgAN, with the GA/AA
genotypes (carriage of the A-allele) being associated with
a worse prognosis. The GA/AA genotypes were signifi-
cantly over-represented in group B (fast progressors, OR
for the GA/AA genotypes: 1.25, 95% CI 1.07–1.47, P =
0.012) (Fig. 1). The frequency of the A-allele was also sig-
nificantly higher among fast progressors (G-allele: 0.30,
A-allele: 0.70) than in slow progressors (G-allele: 0.47, A-
allele: 0.53, P <0.01). In the Kaplan-Meier analysis of kid-
ney survival, patients with the GA/AA genotypes showed
a significantly worse outcome (6.3 ± 0.8 years) compared
with the GG genotype (11.4 ± 2.8 years, mean ± SE,
P < 0.05) (Fig. 2). The IL-10 polymorphism remained an
independent risk factor for progression in multivariate
analysis (Cox regression model), including initial serum
0
25
50
75
100
%
GG GA/AA
IL-10 gene G-1082A polymorphism
Slow progressors (N = 47)
Fast progressors (N = 21)
P < 0.05 †
Fig. 3. Genotype distribution of IL-10 gene G-1082A polymorphism
in group A (slow progressors) and group B (fast progressors) in patients
with biopsy-proven FSGS (N = 68). †Chi-square test.
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Fig. 4. Kaplan-Meier analysis of the kidney survival in patients with
biopsy-proven FSGS (N = 68) in relationship with the IL-10 gene G-
1082A polymorphism. Number of patients at risk, 5 years after renal
biopsy: GG, N = 9; GA/AA, N = 17; 10 years after renal biopsy: GG,
N = 5; GA/AA, N = 6. †Log-rank test.
creatinine, proteinuria, and blood pressure (HR for low
IL-10 GA/AA genotypes: 1.48, 95.0% CI 1.02–1.81, P <
0.05).
Focal segmental glomerulosclerosis. A significant asso-
ciation of IL-10 gene polymorphism with the progression
of FSGS was also observed. The GA/AA genotypes was
significantly more frequent among patients with FSGS
belonging to group B (fast progressors) compared to
group A (slow progressors, OR for the GA/AA geno-
types: 1.44, 95% CI: 1.07–1.93, P < 0.05, figure 3). The
frequency of the A-allele was also significantly higher
in group B (0.62) than in group A (0.43, P < 0.05). A
worse outcome was observed in the Kaplan Meier analy-
sis of renal survival in patients carrying the GA/AA geno-
types (6.2 ± 0.8 years) than in the GG genotype genotype
(10.6 ± 1.6 years, mean ± SE, P < 0.05) (Fig. 4). In a Cox
regression model IL-10 polymorphism remained as an in-
dependent risk factor for progression (multivariate anal-
ysis including initial serum creatinine and blood pressure;
HR for the GA/AA genotypes: 1.57, 95.0% CI 1.03–2.41,
P < 0.05).
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DISCUSSION
In view of the important role that cytokines are thought
to play in the development of renal injury, we assessed the
effects of a genetic variant of IL-10 gene on the progres-
sion of IgA nephropathy and focal segmental glomeru-
losclerosis. We found evidence of genetically determined
subgroups of patients predisposed to accelerated loss of
renal function and earlier onset of ESRD.
IgA nephropathy is initiated by glomerular deposition
of polymeric IgA. In view of the wide clinical range of
IgAN, it may be assumed that there is more than one
pathogenic mechanism, and that mesangial IgA deposi-
tion may well be a final common pathway for more than
one type of IgA immune system abnormality [14]. Al-
tered metabolism of polymeric IgA (decreased produc-
tion by the mucosa [15] and increased by bone marrow
[16]), and impaired IgA glycosylation and clearance [17]
have been implicated. Although the events that lead to
IgA deposition and the initiation of glomerular inflam-
mation are thought to be specific to IgAN, subsequent
processes involving inflammatory injury and promoting
renal scarring are likely to be generic (with few differ-
ences) to other chronic glomerular diseases [14]. Trans-
forming growth factor-beta (TGF-b) and platelet-derived
growth factor (PDGF) are mainly involved in this pro-
cess [18], but other cytokines such as IL-1 [19], IL-6 [19,
20], and tumor necrosis factor-alpha (TNF-a) [19] have
also been implicated. Although the role of immunosup-
pressive agents in the therapy of IgAN is still contro-
versial [21, 22], the reduction of proteinuria achieved in
IgAN patients with normal cholesterol levels by CoA
reductase inhibitors [23] underlines the significance of
inflammatory mechanisms in IgAN. Likewise, although
the pathogenesis of FSGS remains obscure, increasing
amounts of information are becoming available regard-
ing factors that may account for the progression of the
disease. Prominent among them once again are TGF-b
[24, 25] and PDGF [26], but other cytokines like TNF-a
[27] seem to play an important role as well. It is therefore
logical to consider polymorphisms within genes control-
ling this cytokine network as candidates for elucidating
the variable clinical course of primary glomerulonephritis
and IgAN, or FSGS in particular.
IL-10 exerts its actions on a variety of cells. Its ef-
fects are both complex and varied. The earliest described
role of IL-10 was that of a “cytokine synthesis inhibitory
factor” (CSIF). IL-10 was characterized as a product of
Th2 cells that down-regulated the production of INFc,
IL-2, and TNF-b by Th1 cells [28]. It decreases the
surface expression of major histocompatibility complex
(MHC) class II molecules on a variety of antigen pre-
senting cells, down-regulates costimulatory pathways as
intracellular adhesion molecule-1 (ICAM-1) expression,
and inhibits IL-2 production by the T cells, all this result-
ing in decreased antigen-simulated T-cell proliferation
of CD4+ Th cells. Furthermore, IL-10 inhibits the syn-
thesis of proinflammatory cytokines (TNF-a, IL-1, IL-6,
IL-8). However, in addition to these anti-inflammatory
effects, IL-10 promotes B-cell activation, regulates im-
munoglobin class switching, and maintains B-cell viability
by inhibiting apoptosis [10].
Higher levels [29] and higher transcriptional expres-
sion [30] of IL-10 have been demonstrated in white blood
cells from patients with IgAN. Both IL-10 mRNA and IL-
10 protein levels correlated to the severity of glomeru-
lar lesions in biopsies of patients with IgAN [31]. The
presence of IL-10 in severe lesions may reflect activa-
tion of protective mechanisms in the context of severe
glomerular injury. Knockout IL-10–deficient mice devel-
oped functionally and histologically more exaggerated
glomerulonephritis in an anti-GBM (glomerular base-
ment membrane) model [32]. In an experimental model
of mesangial proliferative glomerulonephritis, adminis-
tration of IL-10 diminished inflammatory cell recruitment
and mesangial cell proliferation [33]. Gene transfer of the
human IL-10 gene, leading to increased IL-10 expression,
prevented the development of an animal model of FSGS
[34]. It is not clear to what extent the anti-inflammatory
and antiproliferative effects of IL-10 on renal cells are
direct, and to what extent they are mediated through
modulation of other cytokines, for example, through the
described inhibition of TNF-a secretion from peripheral
blood monocytes in patients with IgAN [35].
IL-10 gene coding for the 160 amino acid long protein
has been mapped to chromosome 1 [36]. Regulatory se-
quences have been identified between position –1100 and
–900 in the promoter of the IL-10 gene [37]. A polymor-
phism in the form of a single base pair substitution (sub-
stitution of guanine with adenine in codon −1082) in this
promoter region was found to correlate with significant
decreases in mitogen (concanavalin A) stimulated IL-
10 production by peripheral mononuclear cells [11]. This
mutation might alter a specific transcription factor recog-
nition site, and consequently affect transcriptional activa-
tion and IL-10 production. The polymorphism lies within
a putative external transcribed spacer (ETS) recognition
site [37], and may therefore affect the binding of this tran-
scription factor, which has been shown to act as a negative
regulator of IL-2 production [38].
Increased frequency of the GA/AA genotypes was
reported in patients with rheumatoid arthritis [39], We-
gener’s granulomatosis [40], Crohn’s disease, and ulcer-
ative colitis [12]. G-1082A polymorphism has also been
associated with the acute rejection rate [41] and long-
term graft survival [42] after renal transplantation, and
the GA/AA genotypes predicted a higher cardiovascular
morbidity in dialysis patients [43].
In the present study we investigated the relationship
of IL-10 G-1082A genotype with clinical outcomes in pa-
tients with IgAN and FSGS. No significant difference
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was observed in the allele frequencies of patients and
control subjects. Thus, the examined polymorphism gave
no indication of a predisposition for the development
of these glomerulonephritis forms. Furthermore, there
were no significant differences in initial renal function,
proteinuria, and blood pressure in patients with differ-
ent genotypes. Patients with FSGS carrying the GA/AA
genotype, which has been associated with reduced IL-
10 production in vitro [11] and in vivo [12], underwent
renal biopsy at a younger age. G-1082A polymorphism
was associated with the progression of both IgAN and
FSGS, with the GA/AA genotypes being connected with
a worse prognosis. The GA/AA genotypes were signifi-
cantly over-represented among fast progressors, and pa-
tients carrying it showed a significantly worse outcome in
the Kaplan-Meier analysis of kidney survival. The IL-10
polymorphism remained as an independent risk factor
for progression in multivariate analysis. To our knowl-
edge, there are no earlier reports of IL-10 gene G-1082A
polymorphism in patients with IgAN or FSGS.
Mechanisms leading to progressive glomerular scar-
ring, in which IL-10 could play an important regulatory
role, although not specific to IgAN or FSGS, relate to the
patient’s proclivity toward renal insufficiency. IL-10 gene
G-1082A polymorphism is most likely not a specific ini-
tiator for these forms of glomerulonephritis, but rather,
a general promoter of progressive renal failure. It is be-
yond doubt that the progression of IgAN and FSGN is
under the influence of many factors, and that genetic poly-
morphisms are merely one component in this complex
setting. At the present time their significance is not suf-
ficient to predict clinical outcomes in individuals so that
clinical decisions could be based on them. Nevertheless,
they are one of the future perspectives. The fact that IL-
10 increases the concentration of glucocorticoid-binding
sites in human nonocytes [44], and cyclosporine A influ-
ences the IL-10 levels [45], leaves room for speculation
regarding a possible impact of IL-10 gene G-1028A poly-
morphism on the response to immunosuppressive agents.
Larger randomized studies with standardized antihyper-
tensive and immunosuppressive protocols are required
to test this hypothesis and validate our results.
CONCLUSION
This study suggests that the IL-10 gene GA/AA
genotype is a risk factor for accelerated progression
in Caucasian patients with IgA nephropathy and focal
segmental glomerulosclerosis. IL-10 gene G-1082A poly-
morphism is one of the parameters that should be de-
termined in upcoming prospective studies, and could
be used in the future for a more accurate predic-
tion of progression, and could provide new options
for the clinical management of patients with primary
glomerulonephritis.
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